Phoenix-backed Sygnature Discovery completed the acquisition of XenoGesis.

Phoenix Equity Partners-backed Sygnature Discovery, a drug discovery company, completed the acquisition of XenoGesis, the UK’s largest independent laboratory-based CRO. Financial terms were not disclosed. "This acquisition effectively doubles the size of our DMPK department (established in 2015), broadening our discovery and development expertise, complementing our existing service-offering and adding new skills and capabilities," Sygnature Discovery.